Neuro-Oncology: The Podcast cover art

All Episodes

Neuro-Oncology: The Podcast — 153 episodes

#
Title
1

Neuro-oncology Narratives What happens when the provider leaves the room?

2

Hot Topic: Part 2: Radiation for Parenchymal Brain Metastases

3

Hot Topics: Part 1: Radiation for Leptomeningeal Disease

4

Author Interview: Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma

5

Hot Topics: Leptomeningeal Disease and Liquid Biopsy

6

Neuro-Oncology Nugget: Synthetic Super-Enhancer Gene Therapy for Glioblastoma

7

Hot Topics: Integrative Neuro-Oncology

8

SNOBound: Career Advice with Dr. Justin Lathia

9

Author Interviews: cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas

10

A Conversation on Career Journeys with SNO's Young Investigator Committee Chairs

11

Neuro-onc Narratives: Two Insiders, One Diagnosis: A Neurosurgeon and Healthcare Leader on Living with GBM

12

Ivosidenib in predominantly recurrent IDH1-mutant glioma: A single-institution experience

13

Author Interview: Prospective biopsy-controlled validation of an AI model for predicting glioblastoma infiltration: Results from the SupraGlio trial

14

Neuro-Oncology Nugget: GT-20 Phase 1 Trial — Personalized Neoantigen DNA Vaccine for MGMT Unmethylated Glioblastoma

15

Author Interview Series SNO Podcast May 2026

16

Neuro-Oncology Narrative

17

Hot Topics: Wellness in Neuro-oncology

18

Neuro-Oncology Nugget: Phase 1/2 BT008NA Trial — Focused Ultrasound + Temozolomide for High-Grade Glioma

19

SNObound: Career description and advice from Dr. Ryan Cecchi in Neuropathology

20

SNObound: Career description and advice from Dr. Ryan Cecchi in Neuropathology

21

CATNON Conclusion: Closure on concurrent chemotherapy in IDHmt Grade 3 Astrocytoma

22

Hot Topics: What's next in neuro-oncology

23

Neuro-Oncology Nugget: Career Development Outreach from SNO

24

Neuro-onc Narratives: An Interview with Caroline Catlin

25

Author Interview: "DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma"

26

Hot Topics: AYA in Neuro-Oncology

27

Neuro-Oncology Nugget: Bivalent EGFR/IL13Rα2 CAR T Cells for Recurrent Glioblastoma

28

SNObound: Career Advice from Dr. Brooke Braman in Radiation Oncology

29

Author Interview: Global analysis of clinical trials for children and adolescents with CNS tumors

30

Neuro-Oncology Nugget: Intracerebroventricular B7-H3 CAR T Cells for DIPG

31

Neuro-onc Narratives: Advocating for patient well-being in neuro-oncology

32

Author Interview: Visual morbidity, long-term outcome, and prognostic factors in infants and young children with optic pathway low-grade glioma

33

Hot Topics: Clinician-Patient Relationship in Neuro-Oncology

34

Neuro-Oncology Nugget: Targeted Radiotherapy Using Rhenium-186 Nanoliposomes for Recurrent Glioma

35

SNObound: Career Advice from Dr. Gelareh Zadeh

36

Author Interview: Ibrutinib for newly diagnosed primary CNS lymphoma

37

Hot Topics: Radiation Hypofractionation in Glioma

38

Neuro-Oncology Nugget: Targeting CDK8 in MYC-Driven Medulloblastoma

39

Neuro-Onc Narratives: Patient Services at the American Brain Tumor Association

40

Author Interview: Post-irradiation chemotherapy in patients with newly diagnosed ependymoma

41

Hot Topics: How longitudinal profiling of glioma informs therapy development

42

Neuro-oncology Nugget: Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma

43

SNObound: Career Advice from Neuro-oncologist, Dr. Lisa DeAngelis

44

Author Interview: Pamiparib and TMZ in recurrent IDHmt gliomas

45

Introduction to Neuro-Oncology: The Podcast 2.0

46

Radiotherapy induced neurocognitive decline

47

QOL and cognitive functioning in patients with oligodendroglioma

48

Post-operative radiation in recurrent grade 1 meningiomas

49

mRNA CAR T against GD2 in high-grade glioma models

50

A transcriptomic atlas of CNS tumors

51

Gut microbiome in primary CNS lymphoma

52

Germline analysis of diffuse midline glioma

53

The proteomic landscape of diffuse midline glioma

54

Radio-Pathomic maps and MR perfusion

55

CSF proteomics in glioma

56

Vorasidenib in IDH mutant glioma

57

KL-50 in post TMZ MMR-deficient GBM

58

Measurable disease per FET-PET vs MRI in GBM

59

Pre-radiation chemotherapy in GBM

60

cIMPACT-NOW Update 8: grading of meningiomas

61

Residual tumor volume and survival after CCNU/TMZ in GBM

62

Alterations in RNA splicing between meningioma DNA methylation groups

63

The immune landscape of IDH mutant and IDHwt glioma

64

Equity-driven applications of AI in neuro-oncology

65

IDH mutant glioma across age groups

66

Contemporary molecular prognostic signatures in glioma

67

FDG PET in PCNSL

68

TMZ and MGMT in elderly GBM patients

69

IDH mutant glioma and IDH inhibitors

70

Leptomeningeal disease, a SNO and ASCO review

71

Cancer stems cell in GBM

72

Drug delivery across the blood-brain barrier

73

Gliomatosis cerebri in children

74

Immunotherapy drives mesenchymal shift in GBM

75

Long-term outcomes of pediatric patients with optic pathway glioma

76

NF1 mutation and neuronal hyperexcitability

77

Postoperative cerebellar mutism

78

Cell cycle checkpoints and alkylating agents

79

Liquid biopsy in CNS lymphoma

80

Immunotherapy for glioblastoma, lessons learned

81

TERTp mutation clonality in glioma

82

Liquid biopsy in H3K27M glioma

83

Glioma genetic profiles and electrophysiologic hyperexcitability

84

Epidemiology of glioma in Belgium

85

The Biology of H3K27M Mutant Gliomas

86

3D tumor volume assessment in PCNSL

87

Brain-tumor related epilepsy; a SNO consensus review

88

Vorasidenib and grading of IDH mutant astrocytoma

89

Insulin feedback and PI3K inhibition in GBM

90

SOX10 indel mutations in schwannomas

91

Dendritic cell vaccines in gliomas

92

Intrathecal trastuzumab for leptomeningeal metastases

93

Short term topiramate for radiation induced cytotoxic edema

94

Venous thromboembolism in gliomas

95

RANO resect

96

Methylation profiling of adult ependymoma

97

Pseudoprogression in IDH-mutant high-grade gliomas

98

Changes in survival outcomes in melanoma patients with brain metastases

99

Radiation therapy and structural brain changes

100

Objective response rate targets for recurrent glioblastoma clinical trials

101

Mitotic count prognostic significance in IDH-mutant astrocytoma in the molecular era

102

Palliative care in neuro-oncology

103

Nivolumab in MGMT methylated GBM

104

IDH mutant gliomas; SNO consensus Review

105

DNA methylation subclass and extent of GBM resection

106

Pre-operative [11C]methionine PET for low-grade glioma

107

The role of T lymphocytes in the glioma pathobiology

108

CDKN2A homozygous deletion in IDH mutant astrocytoma

109

EGFR: the lazarus target in glioblastom

110

Brain metastases; a SNO consensus review: Part 2

111

Brain metastases; a SNO consensus review: Part 1

112

Pediatric IDH mutant gliomas

113

Low-risk meningioma: Outcomes from NRG 0539

114

Selumetinib in children with NF1 and plexiform neurofibroma

115

Targeted therapy for BRAF-mutant pediatric glioma

116

Early/evolving IDH wild-type glioblastoma

117

PI3K signaling in IDH mutant gliomas

118

Cell-free DNA from CSF in pediatric, adolescent and young adult patients

119

Molecular determinants of neurocognitive deficits in glioma

120

H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma

121

Clinical trial accrual for women and minorities in neuro-oncology

122

The clinical utility of next generation sequencing for IDHwt glioblastoma

123

Trabectedin for recurrent grade 2 or 3 meningiomas

124

Glioblastoma cell heterogeneity and plasticity

125

Moleculary integrated grading for meningioma

126

BOLD fMRI in IDH mutant gliomas

127

Glioblastoma subtypes and response to Dasatinib

128

Resection for recurrent brain metastases

129

Incidental Meningiomas

130

Immunosuppression in IDH mutant gliomas

131

Immunotherapy for melanoma brain metastases

132

DNA methylation profiles within the CATNON trial

133

18F FET PET in childhood CNS tumors

134

Checkpoint blockade in atypical meningiomas

135

Molecular signatures of glioma causation

136

Testing methods for MGMT promoter methylation

137

Temozolomide-induced hypermutation in IDH-mutant low-grade gliomas

138

Posterior fossa syndrome

139

Loss of H3K27me3 in meningiomas

140

Loss of H3K27me3 in the Tübingen meningioma cohort

141

A prospective phase II randomized trial of proton radiotherapy vs intensity modulated radiotherapy for patients with newly diagnosed GBM

142

Brain radiotherapy and decline in fine motor skills

143

A serum based DNA methylation assay to detect gliomas

144

PTEN deficiency and proteosome addiction in glioblastoma

145

Cold-Inducible RNA-Binding Protein expression and recurrence of brain metastases

146

The incidence of brain metastases among patients with metastatic breast cancer

147

Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017

148

A large longitudinal study of patients with Neurofibromatosis Type 2.

149

Vorinostat and bevacizumab for recurrent glioblastoma

150

A subset of pediatric thalamic gliomas

151

Supratotal resection of lower-grade gliomas

152

Friends of SNO

153

Announcing Neuro-Oncology: The Podcast